Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan

doi:10.1161/JAHA.120.019529

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 生活保健科技系 > 期刊論文 > Item 310902800/34392

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34392

標題:	Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan
作者:	Hung, Peir-Haur Yeh, Chih-Ching Hsiao, Chih-Yen Muo, Chih-Hsin Hung, Kuan-Yu Tsai, Kuen-Jer
貢獻者:	Chiayi Christian Hosp, Dept Internal Med, Ditmanson Med Fdn Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth China Med Univ, Dept Publ Hlth Taipei Med Univ, Wan Fang Hosp, Canc Ctr Taipei Med Univ, Coll Publ Hlth, Master Program Appl Mol Epidemiol Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm China Med Univ Hosp, Management Off Hlth Data Natl Taiwan Univ Hosp, Dept Internal Med Natl Cheng Kung Univ, Coll Med, Inst Clin Med Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Ctr Clin Med
關鍵字:	end-stage renal disease erythropoietin hemodialysis ischemic stroke
日期:	2021
上傳時間:	2023-11-11 11:49:19 (UTC+8)
出版者:	WILEY
摘要:	Background Targeting higher hemoglobin levels with erythropoietin to treat anemia in patients with chronic kidney disease is associated with increased cardiovascular risk, including that of stroke. The risks of the subtypes of stroke, ischemic, hemorrhagic, and unspecified, following the administration of erythropoietin in patients with end-stage renal disease receiving hemodialysis remain unclear. Methods and results Overall, 12 948 adult patients with end-stage renal disease treated during 1999 to 2010 who had undergone hemodialysis were included. The study end points were the incidences of stroke and its subtypes. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of stroke and its subtypes in erythropoietin recipients compared with nonrecipients. Patients in the erythropoietin cohort did not have an increased risk of stroke compared with those in the nonerythropoietin cohort (adjusted HR, 1.03; 95% CI, 0.92-1.15). Compared with patients in the nonerythropoietin cohort, the risks of ischemic, hemorrhagic, or unspecified stroke were not higher in patients in the erythropoietin cohort (adjusted HRs, 1.08 [95% CI, 0.93-1.26], 0.96 [95% CI, 0.78-1.18], and 1.03 [95% CI, 0.80-1.32], respectively). Increased risks of stroke and its subtypes were not observed with even large annual defined daily doses of erythropoietin (>201). Conclusions Erythropoietin in patients receiving hemodialysis is not associated with increased risk of stroke or any of its subtypes.
關聯:	J AM HEART ASSOC, v.10, n.14
显示于类别:	[生活保健科技系] 期刊論文 [醫務管理系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	256	检视/开启
JAHA.120.019529.pdf		469Kb	Adobe PDF	56	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....